Investigational drug · Phase 3
sustained-release gemcitabine-docetaxel
Also called: NDV-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "sustained-release gemcitabine-docetaxel"
First trial start
2027
Feb 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "sustained-release gemcitabine-docetaxel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bladder (Urothelial, Transitional Cell) Cancer
- Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
- Urothelial Carcinoma Bladder
- Urothelial Carcinoma Recurrent
- Urologic Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "sustained-release gemcitabine-docetaxel" as an intervention, largest first.
- A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerPivotal-lookingNot yet recruiting
Relmada Therapeutics, Inc.Industry
NCT07464145 · 393 participants (planned) · Start Feb 2027 · Primary completion Dec 2029
Drug: NDV-01 (sustained-release gemcitabine-docetaxel) · For: Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Urothelial Carcinoma Bladder and 2 more
- A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line TherapyPivotal-lookingWithdrawn
Relmada Therapeutics, Inc.Industry
NCT07342517 · 0 participants · Start Jun 30, 2026 · Primary completion Jun 30, 2027
Drug: NDV-01 (sustained-release gemcitabine-docetaxel) · For: Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Urothelial Carcinoma Bladder and 2 more
- A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBTPivotal-lookingWithdrawn
Relmada Therapeutics, Inc.Industry
NCT07313891 · 0 participants · Start May 1, 2026 · Primary completion Sep 1, 2029
Drug: NDV-01 (sustained-release gemcitabine-docetaxel) · For: Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer; Urothelial Carcinoma Bladder and 1 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Bladder (Urothelial, Transitional Cell) Cancer
- TARA-002Phase 33 trials
Protara Therapeutics · Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.